iCellate is a Swedish research and development company focused on cancer research and detection products.
iCellate has raised €4.6M across 2 funding rounds, most recently a round in Feb 2021. Based in Stockholm, Sweden; founded 2011; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount |
|---|
| Investors |
|---|
| 2021-02-10 | Other | €2.4M | — | View deal → |
| 2019-10-01 | Series D+ | €2.2M | — | View deal → |
